Eluxadoline clinical trials
Also written Viberzi and JNJ-27018966.
How each study uses eluxadoline is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the eluxadoline studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 May 2015 · VIBERZI · NDA 206940 (FDA, Drugs@FDA)
- European Union
- 19 Sept 2016 · Truberzi · EMEA/H/C/004098 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 2
Furiex Pharmaceuticals, Inc (3) · AbbVie (2) · Allergan (2) · Temple University (1) · University of North Carolina, Chapel Hill (1)
Studies
Open first, then newest update. How each study uses eluxadoline is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)Enrolling by invitationPhase 3AbbVieNCT04880876Written as 25mg Eluxadoline
- Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in ChildrenCompletedPhase 2AbbVieNCT03339128Written as Eluxadoline
- Investigation of Eluxadoline for Diabetic DiarrheaWithdrawnPhase 2/3Temple UniversityNCT04313088Written as Eluxadoline 100 mg
- Eluxadoline Bile Acid Malabsorption (BAM) StudyCompletedPhase 4AllerganNCT03441581Written as Eluxadoline
- Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With DiarrheaCompletedPhase 2Furiex Pharmaceuticals, IncNCT01130272Written as Eluxadoline
- Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal IncontinenceWithdrawnPhase 2University of North Carolina, Chapel HillNCT03489265Written as Eluxadoline 100 mg
- Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide UseCompletedPhase 4AllerganNCT02959983Written as Eluxadoline
- Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)CompletedPhase 3Furiex Pharmaceuticals, IncNCT01553591Written as Eluxadoline
- Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)CompletedPhase 3Furiex Pharmaceuticals, IncNCT01553747Written as Eluxadoline
Codes
What other systems call eluxadoline · ClinicalTrials.gg INT006353
- MeSH (NLM) C583636eluxadolineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 45TPJ4MBQ1ELUXADOLINEConfirmed FDA, NLM, Wikidata
- RxNorm 1653781Confirmed FDA, Wikidata
- Wikidata Q20539232eluxadolineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166725EluxadolineOne source FDA
- DrugBank DB09272One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C583636 | eluxadoline | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 45TPJ4MBQ1 | ELUXADOLINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1653781 | — | Confirmed FDA, Wikidata |
| Wikidata | Q20539232 | eluxadoline | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166725 | Eluxadoline | One source FDA |
| DrugBank | DB09272 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.